Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2011-03-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-011-1433-2PMID 21394499PMCID PMC3405734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

  2011cited by this paper
• Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel

  2011cited by this paper
• American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Expanding the criteria for BRCA mutation testing in breast cancer survivors.

  2010cited by this paper
• A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing.

  2009cited by this paper
• Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing

  2009cited by this paper
• Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups.

  2009cited by this paper
• The prevalence of BRCA1 mutations among young women with triple-negative breast cancer

  2009cited by this paper
• Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

  2008influential reference
• Basal-like breast cancer: a critical review.

  2008cited by this paper
• Analysis of BRCA1/BRCA2 genes’ contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women

  2008cited by this paper
• Prevalence of BRCA1 mutations in triple negative breast cancer (BC).

  2006cited by this paper
• Basal-like breast cancer and the BRCA1 phenotype

  2006cited by this paper
• Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

  2004influential reference
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

  2004influential reference
• A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment

  2003cited by this paper
• Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families

  2002cited by this paper
• Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.

  2001cited by this paper
• Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.

  2000cited by this paper
• Distinctive gene expression patterns in human mammary epithelial cells and breast cancers.

  1999cited by this paper
• Two-sided confidence intervals for the single proportion: comparison of seven methods.

  1998cited by this paper
• Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women

  1997cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Probable Inference, the Law of Succession, and Statistical Inference

  1927cited by this paper

• Constitutional Epimutations: From Rare Events Toward Major Cancer Risk Factors?

  2025cites this paper
• Germline Variants in the Immune Response-Related Genes: Possible Modifying Effect on Age-Dependent BRCA1 Penetrance in Breast Cancer Patient

  2025cites this paper
• Racial and socioeconomic disparities in triple-negative breast cancer treatment

  2024cites this paper
• Constitutional BRCA1 Epimutations: A Key for Understanding Basal-Like Breast and High-Grade Serous Ovarian Cancer

  2024cites this paper
• FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer

  2024cites this paper
• Immunotherapy and its racial specificity for breast cancer treatment in Asia: a narrative review

  2024cites this paper
• Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies.

  2023cites this paper
• Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?

  2023cites this paper
• High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level

  2022cites this paper
• Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype

  2022cites this paper
• Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

  2022cites this paper
• Role of Moderate Risk Suseptibilty Genes in Development of Breast Cancer

  2022cites this paper
• PREVALENCE OF BRCA1 AND BRCA2 MUTATIONS AMONG BREAST AND OVARIAN CANCER PATIENTS IN NORTHERN EMIRATES

  2022cites this paper
• The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis.

  2022cites this paper
• APIR: Aggregating Universal Proteomics Database Search Algorithms for Peptide Identification with FDR Control

  2021cites this paper
• Clinical Outcomes Among Major Breast Cancer Subtypes After Neoadjuvant Chemotherapy: Impact on Breast Cancer Recurrence and Survival

  2021cites this paper
• APIR: a universal FDR-control framework for boosting peptide identification power by aggregating multiple proteomics database search algorithms

  2021cites this paper
• Molecular biological subtypes of breast cancer in BRCA1 mutation carriers

  2021cites this paper
• Herediter ve Ailesel Meme Kanserlerinin Aile Öyküsü ile Klinikopatolojik Özelliklerinin Karşılaştırılması; Tek Merkez Deneyimi

  2021cites this paper
• Molecular and Clinical Significance of Stanniocalcin-1 Expression in Breast Cancer Through Promotion of Homologous Recombination-Mediated DNA Damage Repair

  2021influential citation
• Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India

  2021cites this paper
• The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.

  2021cites this paper
• PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice

  2020cites this paper
• PARP-ингибиторы в лечении больных метастатическим раком молочной железы с герминальными мутациями в генах BRCA1/2. Опыт применения талазопариба в клинической практике

  2020cites this paper
• The hispanic landscape of triple negative breast cancer.

  2020cites this paper
• Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems

  2020cites this paper
• Using Phosphatidylinositol Phosphorylation as Markers for Hyperglycemic Related Breast Cancer

  2020cites this paper
• Screening of BRCA1 and BRCA2 germline mutations in unselected triple‐negative breast cancer patients: A series from north of Morocco

  2020cites this paper
• Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer

  2020cites this paper
• A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

  2019cites this paper
• Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.

  2019cites this paper
• Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer

  2019cites this paper
• The role of BRCA1/2 in hereditary and familial breast and ovarian cancers

  2019cites this paper
• Practical Cancer Genetics and Genomics in Women's Health.

  2019cites this paper
• Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.

  2019cites this paper
• Therapeutic landscape in mutational triple negative breast cancer

  2018cites this paper
• Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition

  2018cites this paper
• Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis

  2018cites this paper
• Triple-Negative Breast Cancer: Clinical Features

  2018influential citation
• The Genetics of Triple-Negative Breast Cancer

  2018cites this paper
• Special Issues in Young Women with Triple-Negative Breast Cancer

  2018cites this paper
• Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing

  2018cites this paper
• Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation

  2018influential citation
• Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women

  2018cites this paper
• High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population

  2018cites this paper
• Emerging therapeutic modalities of PARP inhibitors in breast cancer.

  2018cites this paper
• Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies

  2017cites this paper
• BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.

  2017cites this paper
• Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women

  2017cites this paper
• Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow‐up

  2017cites this paper
• Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort

  2017cites this paper
• Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers

  2017cites this paper
• Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women.

  2017cites this paper
• Next GeNeratioN SequeNciNG revealS HiGH PrevaleNce

  2017cites this paper
• Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers

  2016cites this paper
• Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer

  2016cites this paper
• Genetics of triple-negative breast cancer: Implications for patient care.

  2016cites this paper
• Primary Immunoprevention: The Great Unmet Need for Controlling Breast Cancer.

  2016cites this paper
• REVIEW Recent Progress in Triple Negative Breast Cancer Research

  2016influential citation
• Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple‐negative breast cancer, adversely affects survival

  2016cites this paper
• Recent Progress in Triple Negative Breast Cancer Research.

  2016influential citation
• Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience

  2015cites this paper
• Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis

  2015cites this paper
• Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population

  2015cites this paper
• Hereditary breast cancer syndromes and genetic testing

  2015cites this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cites this paper
• Understanding Triple Negative Breast Cancer

  2015cites this paper
• Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries

  2015cites this paper
• Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

  2015cites this paper
• What common biomarkers characterize a triple-negative profile in breast cancer?

  2015cites this paper
• Triple-negative breast cancer: advancements in characterization and treatment approach

  2015cites this paper
• Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer

  2015cites this paper
• The prevalence of BRCA1/2 mutations of triple-negative breast cancer patients in Xinjiang multiple ethnic region of China

  2014cites this paper
• Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers

  2014cites this paper
• Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers

  2014cites this paper
• Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family History–Based Testing

  2014cites this paper
• Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy

  2014cites this paper
• Bench-to-bedside challenges in developing immune protection against breast cancer

  2014cites this paper
• Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

  2014cites this paper
• Squamous Cell Carcinoma of the Pancreas in a Patient with Germline BRCA2 Mutation-Response to Neoadjuvant Radiochemotherapy

  2014cites this paper
• Genetic Susceptibility to Triple‐Negative Breast Cancers

  2014cites this paper
• Risk of having BRCA1 mutation in high‐risk women with triple‐negative breast cancer: a meta‐analysis

  2014cites this paper
• “I Do Not Want My Baby to Suffer as I Did”; Prenatal and Preimplantation Genetic Diagnosis for BRCA1/2 Mutations: A Case Report and Genetic Counseling Considerations

  2014cites this paper
• THE ROLE OF GERMLINE BRCA1 FOUNDER MUTATIONS AND SOMATIC TP53 MUTATIONS IN THE TRIPLE-NEGATIVE BREAST CANCER SUBTYPE

  2014cites this paper
• Genetic susceptibility to triple-negative breast cancer.

  2013cites this paper
• Deleterious BRCA 2 Mutation in a 40-Year-Old Woman With Inflammatory Breast Cancer and Strong Family History of Maternal Inflammatory Breast Cancer at a Young Age

  2013cites this paper
• Chapter 60 – Breast Cancer

  2013cites this paper
• Asociación entre mutaciones germinales en BRCA1 y cáncer de mama triple negativo diagnosticado antes de los 50 años y sin historia familiar

  2013cites this paper
• Androgen receptor in triple negative breast cancer.

  2013cites this paper
• Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

  2013cites this paper
• Triple-negative breast cancer and PTEN ( phosphatase and tensin homologue ) loss are predictors of BRCA 1 germline mutations in women with early-onset and familial breast cancer , but not in women with isolated late-onset breast cancer

  2012cites this paper
• Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.

  2012cites this paper
• Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

  2012influential citation
• Frequency of triple-negative breast cancer in BRCA1 mutation carriers: comparison between common Ashkenazi Jewish and other mutations.

  2012cites this paper
• Treatment for triple-negative breast cancer

  2012cites this paper
• Triple-negative breast cancer and PTEN (phosphatase and tensin homologue)loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer

  2012cites this paper
• Breast conserving surgery and radiation as a choice for patients with BRCA mutations

  2012cites this paper
• Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer

  2012cites this paper
• BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years

  2012cites this paper
• Targeting triple-negative breast cancer: optimising therapeutic outcomes.

  2012cites this paper